Yves Beguin

Yves Beguin

Liege, WAL, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 229 publications

Adverse Prognostic Impact of Pretransplant Serum Ferritin and Hepcidin on Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.

Adverse Prognostic Impact of Pretransplant Serum Ferritin and Hepcidin on Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.

Journal: American journal of hematology

Published: February 01, 2026

ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC.

ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC.

Journal: Bone marrow transplantation

Published: November 30, 2025

Development of a humanized mouse model of graft-versus-host disease to assess human regulatory T cell function.

Development of a humanized mouse model of graft-versus-host disease to assess human regulatory T cell function.

Journal: Frontiers in immunology

Published: October 01, 2025

Whipple's disease presenting with bone marrow findings mimicking prefibrotic myelofibrosis: A diagnostic pitfall.

Whipple's disease presenting with bone marrow findings mimicking prefibrotic myelofibrosis: A diagnostic pitfall.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: August 11, 2025

Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.

Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.

Journal: Leukemia

Published: June 23, 2025

EEG characteristics of central nervous system graft-versus-host disease.

EEG characteristics of central nervous system graft-versus-host disease.

Journal: Journal of neurophysiology

Published: May 27, 2025

Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)

Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)

Journal: Bulletin du cancer

Published: February 10, 2025

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

Journal: American journal of hematology

Published: January 24, 2025

The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.

The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.

Journal: Bone marrow transplantation

Published: November 09, 2024

Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review.

Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review.

Journal: Stem cell research & therapy

Published: September 17, 2024

Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.

Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.

Journal: PLoS genetics

Published: July 19, 2024

Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with hematological malignancies.

Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with hematological malignancies.

Journal: Current research in translational medicine

Published: June 10, 2024

Showing 1-12 of 229

Last Updated: 09/26/2026